Welcome, Guest. Please login or register.
August 18, 2019, 11:06:23 am

Login with username, password and session length


Members
  • Total Members: 6116
  • Latest: JuliaG
Stats
  • Total Posts: 54293
  • Total Topics: 4598
  • Online Today: 70
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 1
Guests: 68
Total: 69

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA Approves New Targeted Treatment for Liver Cancer  (Read 221 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 632
    • Hep Mag
FDA Approves New Targeted Treatment for Liver Cancer
« on: March 18, 2019, 10:32:27 am »
On January 14, the Food and Drug Administration approved the multikinase inhibitor Cabometyx (cabozantinib) for people with previously treated hepatocellular carcinoma (HCC), the most common type of liver cancer.

This approval was based on a clinical trial showing that Cabometyx improved both progression-free survival—meaning patients were still alive without worsening of disease—and overall survival in people previously treated with Nexavar (sorafenib).

For more...
https://www.hepmag.com/article/fda-approves-new-targeted-treatment-liver-cancer

 


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.